References
- Abbas Abidi SM, Howard EW, Dmytryk JJ, Pento JT (1997). Differential influence of antiestrogens on the in vitro release of gelatinases (type IV collagenases) by invasive and non-invasive breast cancer cells. Clin Exp Metastasis, 15, 432-9. https://doi.org/10.1023/A:1018458406797
- Ahluwalia AS, Tarnawski A (2012). Critical role of hypoxia sensor-HIF-1 in VEGF gene activation. implications for angiogenesis and tissue injury healing. Curr Med Chem, 19, 90-7. https://doi.org/10.2174/092986712803413944
- Applanat MP, Buteau-Lozano H, Herve MA, Corpet A (2008). Vascular endothelial growth factor is a target gene for estrogen receptor and contributes to breast cancer progression. Adv Exp Med Biol, 617, 437-44. https://doi.org/10.1007/978-0-387-69080-3_42
- Azuma H, Banno K, Yoshimura T (1976). Pharmacological properties of N-(3', 4'- dimethoxycinnamoyl) anthranilic acid (N-5'), a new anti-atopic agent. Br J Pharmacol, 58, 483-8. https://doi.org/10.1111/j.1476-5381.1976.tb08614.x
- Banerjee S, Dowsett M, Ashworth A, Martin LA (2007). Mechanisms of disease: angiogenesis and the management of breast cancer. Nat Clin Pract Oncol, 4, 536-50.
- Bergers G, Benjamin LE (2003). Tumorigenesis and the angiogenic switch. Nat Rev Cancer, 3, 401-10. https://doi.org/10.1038/nrc1093
- Chakrabarti R, Subramaniam V, Abdalla S, Jothy S, Prud'homme GJ (2009). Tranilast inhibits the growth and metastasis of mammary carcinoma. Anticancer Drugs, 20, 334-45. https://doi.org/10.1097/CAD.0b013e328327994e
- Cole MP, Jones CT, Todd ID (1971). A new anti-oestrogenic agent in late breast cancer. An early clinical appraisal of ICI46474. Br J Cancer, 25, 270-5. https://doi.org/10.1038/bjc.1971.33
- Dabrosin C, Margetts PJ, Gauldie J (2003). Estradiol increases extracellular levels of vascular endothelial growth factor in vivo in murine mammary cancer. Int J Cancer, 107, 535-40. https://doi.org/10.1002/ijc.11398
- Ferrara N, Gerber HP, LeCouter J (2003). The biology of VEGF and its receptors. Nat Med, 9, 669-76. https://doi.org/10.1038/nm0603-669
- Folkman J (1990). What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst, 82, 4-6. https://doi.org/10.1093/jnci/82.1.4
- Garvin S, Dabrosin C (2003). Tamoxifen inhibits secretion of vascular endothelial growth factor in breast cancer in vivo, Cancer Res, 63, 8742-48.
- Garvin S, Nilsson U, Dabrosin C (2005). Effects of oestradiol and tamoxifen on VEGF, soluble VEGFR-1, and VEGFR-2 in breast cancer and endothelial cells, Br J Cancer, 93, 1005-10. https://doi.org/10.1038/sj.bjc.6602824
- Garvin S, Nilsson UW, Huss FR, Kratz G, Dabrosin C (2006). Estradiol increases VEGF in human breast studied by whole-tissue culture. Cell Tissue Res, 325, 245-51. https://doi.org/10.1007/s00441-006-0159-7
- Gialeli C, Theocharis AD, Karamanos NK (2011). Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting. The FEBS Journal, 1, 16-27.
- Hsieh GS, Acosta D (1991). Dithranol-induced cytotoxicity in primary cultures of rat epidermal keratinocytes. Toxicol Appl Pharmacol, 107, 16-26. https://doi.org/10.1016/0041-008X(91)90326-A
- Izumi K, Mizokami A, Shima T, et al (2010). Preliminary results of tranilast treatment for patients with advanced castration resistant prostate cancer. Anticancer Res, 30, 3077-81.
- Jordan VC (2003). Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov, 2, 205-13. https://doi.org/10.1038/nrd1031
-
Kazi AA, Koos RD (2007). Estrogen-induced activation of hypoxia inducible factor 1
$\alpha$ (HIF-1$\alpha$ ), vascular endothelial growth factor (VEGF) expression, and edema in the uterus are mediated by the phosphatidylinositol 3-kinase (PI3K)/Akt pathway. Endocrinology, 148, 2363-74. https://doi.org/10.1210/en.2006-1394 - Khosravi Shahi P, Soria Lovelle A, Perez Manga G (2009). Tumoral angiogenesis and breast cancer. Clin Transl Oncol, 11, 138-42. https://doi.org/10.1007/S12094-009-0329-7
- Kousidoua OC, Berdiakib A, Kletsasc D, et al (2008). Estradiol-estrogen receptor: a key interplay of the expression of syndecan-2 and metalloproteinase-9 in breast cancer cells. Mol Oncology, 2, 223-32. https://doi.org/10.1016/j.molonc.2008.06.002
- Kumar BNP, Rajput S, Kumar Dey K, et al (2013). Celecoxib alleviates tamoxifen-instigated angiogenic effects by ROS-dependent VEGF/VEGFR2 autocrine signaling. BMC Cancer, 13, 273. https://doi.org/10.1186/1471-2407-13-273
- Linderholm B, Bergqvist J, Hellborg H, et al (2009). Shorter survival-times following adjuvant endocrine therapy in oestrogen- and progesterone-receptor positive breast cancer overexpressing HER2 and/or with an increased expression of vascular endothelial growth factor. Med Oncol, 26, 480-90. https://doi.org/10.1007/s12032-008-9157-9
- Littlepage LE, Sternlicht MD, Rougier N, et al (2010). Matrix metalloproteinases contribute distinct roles in neuroendocrine prostate carcinogenesis, metastasis, and angiogenesis progression. Cancer Res, 70, 2224-34. https://doi.org/10.1158/0008-5472.CAN-09-3515
- Lymperatou D, Efstathia Giannopoulou E, Koutras AK, Kalofonos HP (2013). The Exposure of Breast Cancer Cells to Fulvestrant and Tamoxifen Modulates Cell Migration Differently. Bio Med Res Int, 2013, 147514.
- Mitsuno M Kitajima Y, Ohtaka K, et al (2010). Tranilast strongly sensitizes pancreatic cancer cells to gemcitabine via decreasing protein expression of ribonucleotide reductase 1. Int J Oncol, 36, 341-9.
- Nilsson U, Garvin S, Dabrosin C (2007). MMP-2 and MMP-9 activity is regulated by estradiol and tamoxifen in cultured human breast cancer cells. Breast Cancer Res Treat, 102, 253-61. https://doi.org/10.1007/s10549-006-9335-4
- Nilsson UW, Dabrosin C (2006). Estradiol and tamoxifen regulate endostatin generation via matrix metalloproteinase activity in breast cancer in vivo. Cancer Res, 66, 4789-94. https://doi.org/10.1158/0008-5472.CAN-05-4012
- Noguchi N, Kawashiri S, Tanaka A, et al (2003). Effects of fibroblast growth inhibitor on proliferation and metastasis of oral squamous cell carcinoma. Oral Oncol, 39, 240-7. https://doi.org/10.1016/S1368-8375(02)00092-1
- Perrot-Applanat M, Di Benedetto M (2012). Autocrine functions of VEGF in breast tumor cells: adhesion, survival, migration and invasion. Cell Adh Migr, 6, 547-53. https://doi.org/10.4161/cam.23332
- Petrangeli E, Lubrano C, Ortolani F, et al (1994). Estrogen receptors: new perspectives in breast cancer management. J Steroid Biochem Mol Biol, 49, 327-31. https://doi.org/10.1016/0960-0760(94)90275-5
- Pilips N, McFadden K (2004). Inhibition of transforming growth factor-beta and matrix metalloproteinases by estrogen and prolactin in breast cancer cells. Cancer Lett, 206, 63-8. https://doi.org/10.1016/j.canlet.2003.10.019
- Rajput S, Kumar BN, Sarkar S, et al (2013). Targeted apoptotic effects of thymoquinone and tamoxifen on XIAP mediated AKT regulation in breast cancer. Plos One, 8, 61342. https://doi.org/10.1371/journal.pone.0061342
- Schneider BP, Sledge Jr GW (2007). Drug insight: VEGF as a therapeutic target for breast cancer. Nat Clin Pract Oncol, 4, 181-9.
- Subramaniam V, Ace O, Prud’homme GJ, et al (2011). Tranilast treatment decreases cell growth, migration and inhibits colony formation of human breast cancer cells. Exp Mol Pathol, 90, 116-22. https://doi.org/10.1016/j.yexmp.2010.10.012
- Subramaniam V, Chakrabarti R, Prud'homme GJ, Jothy S (2010). Tranilast inhibits cell proliferation and migration and promotes apoptosis in murine breast cancer. Anticancer Drugs, 21, 351-61. https://doi.org/10.1097/CAD.0b013e328334992c
- Van den Brule FA, Engel J, Stetler-Stevenson WG, et al (1992). Genes involved in tumor invasion and metastasis are differentially modulated by estradiol and progestin in human breast-cancer cells. Int J Cancer, 52, 653-7. https://doi.org/10.1002/ijc.2910520426
- Versteeg HH, Schaffner F, Kerver M, et al (2008). Inhibition of tissue factor signaling suppresses tumor growth. Blood, 111, 190-9. https://doi.org/10.1182/blood-2007-07-101048
- Weidner N, Folkman J, Pozza F, et al (1992). Tumor angiogenesis: a new significant andindependent prognostic indicator in early-stage breast carcinoma. J Natl Cancer Inst, 84, 1875-87. https://doi.org/10.1093/jnci/84.24.1875
- Yamamoto M, Yamauchi T, Okano K et al (2009). Tranilast, an anti-allergic drug, down-regulates the growth of cultured neurofibroma cells derived from neurofibromatosis type 1. Tohoku J Exp Med, 217, 193-201. https://doi.org/10.1620/tjem.217.193
Cited by
- Radixin Knockdown by RNA Interference Suppresses Human Glioblastoma Cell Growth in Vitro and in Vivo vol.15, pp.22, 2014, https://doi.org/10.7314/APJCP.2014.15.22.9805
- Cinobufacin Suppresses Cell Proliferation via miR-494 in BGC-823 Gastric Cancer Cells vol.15, pp.3, 2014, https://doi.org/10.7314/APJCP.2014.15.3.1241
- Anticancer Effect of COX-2 Inhibitor DuP-697 Alone and in Combination with Tyrosine Kinase Inhibitor (E7080) on Colon Cancer Cell Lines vol.15, pp.7, 2014, https://doi.org/10.7314/APJCP.2014.15.7.3113
- CYP2D6 Genotype and Risk of Recurrence in Tamoxifen Treated Breast Cancer Patients vol.16, pp.15, 2015, https://doi.org/10.7314/APJCP.2015.16.15.6783
- Prognostic Factors Influencing Clinical Outcomes of Malignant Glioblastoma Multiforme: Clinical, Immunophenotypic, and Fluorescence in Situ Hybridization Findings for 1p19q in 816 Chinese Cases vol.16, pp.3, 2015, https://doi.org/10.7314/APJCP.2015.16.3.971
- AhR ligand aminoflavone suppresses α6-integrin-Src-Akt signaling to attenuate tamoxifen resistance in breast cancer cells vol.234, pp.1, 2018, https://doi.org/10.1002/jcp.27013
- The Role of Desmoplasia and Stromal Fibroblasts on Anti-cancer Drug Resistance in a Microengineered Tumor Model vol.11, pp.5, 2018, https://doi.org/10.1007/s12195-018-0544-9